Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Surgery
Published in: Journal of Gastrointestinal Surgery 1/2010

Open Access 01-01-2010 | 2009 SSAT Plenary Presentation

Improvement in Peripheral Glucose Uptake After Gastric Bypass Surgery Is Observed Only After Substantial Weight Loss Has Occurred and Correlates with the Magnitude of Weight Lost

Authors: Guilherme M. Campos, Charlotte Rabl, Sofia Peeva, Ruxandra Ciovica, Madhu Rao, Jean-Marc Schwarz, Peter Havel, Morris Schambelan, Kathleen Mulligan

Published in: Journal of Gastrointestinal Surgery | Issue 1/2010

Login to get access

Abstract

Introduction

Altered gut and pancreatic hormone secretion may bolster resolution of insulin resistance after Roux-en-Y gastric bypass (RYGB), but the independent effects of weight loss and hormonal secretion on peripheral glucose disposal are unknown.

Methods

Two groups of nondiabetic morbidly obese patients were studied: RYGB followed by standardized caloric restriction (RYGB, n = 12) or caloric restriction alone (diet, n = 10). Metabolic evaluations (euglycemic–hyperinsulinemic clamp, meal tolerance test) were done at baseline and 14 days (both groups) and 6 months after RYGB.

Results

At baseline, body composition, fasting insulin, and glucose and peripheral glucose disposal did not differ between groups. At 14 days, excess weight loss (EWL) was similar (RYGB, 12.7% vs. diet, 10.9%; p = 0.12), fasting insulin and glucose decreased to a similar extent, and RYGB subjects had altered postmeal patterns of gut and pancreatic hormone secretion. However, peripheral glucose uptake (M value) was unchanged in both groups. Six months after RYGB, EWL was 49.7%. The changes in fasting glucose and insulin levels and gut hormone secretion persisted. M values improved significantly, and changes in M values correlated with the % EWL (r = 0.68, p = 0.02).

Conclusions

Improvement in peripheral glucose uptake following RYGB was observed only after substantial weight loss had occurred and correlated with the magnitude of weight lost.
Literature
1.
Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122(3):248–256. e245.CrossRefPubMed
2.
Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222(3):339–350. discussion 350–332.CrossRefPubMed
3.
Buchwald H. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis 2005;1(3):371–381.CrossRefPubMed
4.
Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292(14):1724–1737.CrossRefPubMed
5.
Nguyen NT, Hinojosa M, Fayad C, Varela E, Wilson SE. Use and outcomes of laparoscopic versus open gastric bypass at academic medical centers. J Am Coll Surg 2007;205(2):248–255.CrossRefPubMed
6.
Bikman BT, Zheng D, Pories WJ et al. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab 2008;93(12):4656–4663.CrossRefPubMed
7.
Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 2006;93(2):210–215.CrossRefPubMed
8.
Cummings DE, Flum DR. Gastrointestinal surgery as a treatment for diabetes. JAMA 2008;299(3):341–343.CrossRefPubMed
9.
Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care 2009;32(3):514–520.CrossRefPubMed
10.
Korner J, Inabnet W, Febres G et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009;33(7):786–795.CrossRef
11.
le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246(5):780–785.CrossRefPubMed
12.
Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;31( Suppl 2):S290–296.CrossRefPubMed
13.
Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30(7):1709–1716.CrossRefPubMed
14.
Laferrere B, Teixeira J, McGinty J et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93(7):2479–2485.CrossRefPubMed
15.
Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89(6):2608–2615.CrossRefPubMed
16.
Korner J, Inabnet W, Conwell IM et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006;14(9):1553–1561.CrossRef
17.
Rubino F, Gagner M, Marescaux J. Surgical treatment of type 2 diabetes mellitus. Lancet 2001;358(9282):668–669.CrossRefPubMed
18.
Rodieux F, Giusti V, D’Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008;16(2):298–305.CrossRef
19.
Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE. Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Relat Dis 2005;1(3):358–368.CrossRefPubMed
20.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132(6):2131–2157.CrossRefPubMed
21.
Batterham RL, Heffron H, Kapoor S et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 2006;4(3):223–233.CrossRefPubMed
22.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237(3):E214–223.PubMed
23.
Campos GM, Ciovica R, Rogers SJ et al. Spectrum and risk factors of complications after gastric bypass. Arch Surg 2007;142(10):969–975. discussion 976.CrossRefPubMed
24.
Campos GM, Rabl C, Mulligan K et al. Factors associated with weight loss after gastric bypass. Arch Surg 2008;143(9):877–883. discussion 884.CrossRefPubMed
25.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412–419.CrossRefPubMed
26.
Rao MN, Mulligan K, Schambelan M. HIV infection and diabetes. In Poretsky L, ed. Principles of Diabetes Mellitus. Norwell: Springer, 2009.
27.
Ashrafian H, le Roux CW. Metabolic surgery and gut hormones—a review of bariatric entero-humoral modulation. Physiol Behav 2009;97:620–631.CrossRefPubMed
28.
Ellsmere JC, Thompson CC, Brugge WR et al. Endoscopic interventions for weight loss surgery. Obesity (Silver Spring) 2009;17(5):929–933.CrossRef
29.
Fetner R, McGinty J, Russell C, Pi-Sunyer FX, Laferrere B. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 2005;1(6):589–597. discussion 597–588.CrossRefPubMed
30.
Rubino F, Forgione A, Cummings DE et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244(5):741–749.CrossRefPubMed
31.
Smith BR, Schauer P, Nguyen NT. Surgical approaches to the treatment of obesity: bariatric surgery. Endocrinol Metab Clin North Am 2008;37(4):943–964.CrossRefPubMed
32.
Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009;33(Suppl 1):S33–40.CrossRef
33.
Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007;3(6):597–601.CrossRefPubMed
34.
Guidone C, Manco M, Valera-Mora E et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006;55(7):2025–2031.CrossRefPubMed
35.
Morinigo R, Casamitjana R, Delgado S et al. Insulin resistance, inflammation, and the metabolic syndrome following Roux-en-Y gastric bypass surgery in severely obese subjects. Diabetes Care 2007;30(7):1906–1908.CrossRefPubMed
36.
Perugini RA, Quarfordt SH, Baker S, Czerniach DR, Litwin DE, Kelly JJ. Metabolic characterization of nondiabetic severely obese patients undergoing Roux-en-Y gastric bypass: preoperative classification predicts the effects of gastric bypass on insulin-glucose homeostasis. J Gastrointest Surg 2007;11(9):1083–1090.CrossRefPubMed
37.
Salinari S, Bertuzzi A, Iaconelli A, Manco M, Mingrone G. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. Diabetologia 2008;51(7):1276–1284.CrossRefPubMed
38.
Hagemann D, Holst JJ, Gethmann A, Banasch M, Schmidt WE, Meier JJ. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept 2007;143(1–3):64–68.CrossRefPubMed
39.
le Roux CW, Aylwin SJ, Batterham RL et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243(1):108–114.CrossRefPubMed
40.
Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236(5):554–559.CrossRefPubMed
41.
Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294(1):E15–26.CrossRefPubMed
42.
Mather KJ, Hunt AE, Steinberg HO et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001;86(11):5457–5464.CrossRefPubMed
Metadata
Title
Improvement in Peripheral Glucose Uptake After Gastric Bypass Surgery Is Observed Only After Substantial Weight Loss Has Occurred and Correlates with the Magnitude of Weight Lost
Authors
Guilherme M. Campos
Charlotte Rabl
Sofia Peeva
Ruxandra Ciovica
Madhu Rao
Jean-Marc Schwarz
Peter Havel
Morris Schambelan
Kathleen Mulligan
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 1/2010
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-009-1060-y

Other articles of this Issue 1/2010

Journal of Gastrointestinal Surgery 1/2010 Go to the issue

2009 SSAT Poster Presentation

Subclinical Intestinal Inflammation in Patients with Crohn’s Disease Following Bowel Resection: A Smoldering Fire

GI Image

Inflammatory Pseudotumor of the Esophagus—GI Image

Original Article

Endoscopic and Percutaneous Preoperative Biliary Drainage in Patients with Suspected Hilar Cholangiocarcinoma

Original Article

Airway Infection Predisposes to Peristomal Infection after Percutaneous Endoscopic Gastrostomy with High Concordance Between Sputum and Wound Isolates

2009 SSAT Plenary Presentation

Endoluminal Fundoplication (ELF) for GERD Using EsophyX: a 12-Month Follow-up in a Single-Center Experience

Original Article

Laparoscopic Resection for Inflammatory Bowel Disease: Outcomes from a Nationwide Sample